Skip to main content

Drug Safety

      RT @synovialjoints: Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form
      1 year 5 months ago
      Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r
      RT @synovialjoints: Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory res
      1 year 5 months ago
      Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response, slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K
      Daily Recap: Day One + Two
      RT @drdavidliew: For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs.

      @eu
      1 year 5 months ago
      For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs. @eular_org points to consider SLR: no clear risk, across b/tsDMARDs For too long these patients were unnecessarily asked to ride it out. No more please POS1069 #EULAR2023 @RheumNow https://t.co/7m4Yh0h7rd
      RT @AurelieRheumo: Retro French database study shows reassuring data.

      Overall mortality after IRAEs =similar between p
      1 year 5 months ago
      Retro French database study shows reassuring data. Overall mortality after IRAEs =similar between pts receiving b/tsDMARDs vs. those who don't 70000+ pts treated w/ ICI, 7800+ IRAEs (most frequent colitis) & 330 treated w/ b/tsDMARDs, 10% Rheum IRAE OP0270 @RheumNow #EULAR23 https://t.co/OFNaIU4kzt
      RT @drdavidliew: Can’t escape ORAL Surveillance RCT talk

      Lots of real world data on CV risk & JAKi here
      (with all
      1 year 5 months ago
      Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri
      RT @synovialjoints: JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non signific
      1 year 5 months ago
      JAKi use did not increase CV risk compared to TNF, no difference between Bari and Tofa, non significant increased IRR in patients >65 years, Merel Opdam, Abst#OP0221 #EULAR2023 @RheumNow https://t.co/Pu5X8RHJOY
      RT @drdavidliew: Malignancy in real world datasets:
      do we see differences between DMARDs - particularly JAKi, with ORAL
      1 year 5 months ago
      Malignancy in real world datasets: do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind? RABBIT German data (limited risk window): Point estimates slightly up vs TNFi, esp in high CV risk pts but magnitude not big OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b
      RT @drdavidliew: Men trying to conceive were prev told to avoid MTX. Another myth busted

      Why? Spermatozoa lack the FPGS
      1 year 5 months ago
      Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 @RheumNow (& @ARD_BMJ https://t.co/SDdoNP12oR)
      Day 2 at the international EULAR Congress meeting is always bigger and busier.  There are more sessions to choose from, more bodies fighting for space on the escalators and at the lunch lines,…